Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential effect of an evolving amyloid and tau pathology on brain phospholipids and bioactive lipid mediators in rat models of Alzheimer-like pathology.
Do Carmo S, Kautzmann MI, Bhattacharjee S, Jun B, Steinberg C, Emmerson JT, Malcolm JC, Bonomo Q, Bazan NG, Cuello AC. Do Carmo S, et al. Among authors: emmerson jt. J Neuroinflammation. 2024 Jul 30;21(1):185. doi: 10.1186/s12974-024-03184-7. J Neuroinflammation. 2024. PMID: 39080670 Free PMC article.
Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
Grosser B, Emmerson J, Reitsam NG, Cunningham D, Nankivell M, Langley RE, Allum WH, Trepel M, Märkl B, Grabsch HI. Grosser B, et al. Among authors: emmerson j. Br J Cancer. 2024 Feb;130(3):457-466. doi: 10.1038/s41416-023-02515-4. Epub 2023 Dec 20. Br J Cancer. 2024. PMID: 38123705 Free PMC article.
Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ford AC, Wright-Hughes A, Alderson SL, Ow PL, Ridd MJ, Foy R, Bianco G, Bishop FL, Chaddock M, Cook H, Cooper D, Fernandez C, Guthrie EA, Hartley S, Herbert A, Howdon D, Muir DP, Nath T, Newman S, Smith T, Taylor CA, Teasdale EJ, Thornton R, Farrin AJ, Everitt HA; ATLANTIS trialists. Ford AC, et al. Lancet. 2023 Nov 11;402(10414):1773-1785. doi: 10.1016/S0140-6736(23)01523-4. Epub 2023 Oct 16. Lancet. 2023. PMID: 37858323 Free article. Clinical Trial.
Corrigendum to "Progressive human-like tauopathy with downstream neurodegeneration and neurovascular compromise in a transgenic rat model" [Neurobiol of Disease 184 (2023),106227 / YNBDI_106227].
Emmerson JT, Do Carmo S, Liu Y, Shalhoub A, Liu A, Bonomo Q, Malcolm JC, Breuillaud L, Martinez-Trujillo JC, Cuello AC. Emmerson JT, et al. Neurobiol Dis. 2023 Oct 15;187:106301. doi: 10.1016/j.nbd.2023.106301. Epub 2023 Sep 22. Neurobiol Dis. 2023. PMID: 37741743 Free article. No abstract available.
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
Munir T, Emmerson J, Hockaday A, Oughton JB, Howard D, Phillips D, Neilson J, Pemberton N, Paneesha S, Kennedy B, Rawstron A, Hillmen P. Munir T, et al. Among authors: emmerson j. Br J Haematol. 2022 Dec;199(5):707-719. doi: 10.1111/bjh.18427. Epub 2022 Aug 26. Br J Haematol. 2022. PMID: 36017875 Free PMC article. Clinical Trial.
Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials.
Liu DHW, Šefčovičová N, Emmerson J, Spaans LN, Saito Y, Hutchins G, Nankivell MG, Langley RE, Allum W, Cunningham D, Langer R, Grabsch HI. Liu DHW, et al. Among authors: emmerson j. Eur J Cancer. 2022 Jul;170:140-148. doi: 10.1016/j.ejca.2022.04.026. Epub 2022 May 27. Eur J Cancer. 2022. PMID: 35635935 Free article. Clinical Trial.
71 results